Longitudinal study of 18 children with perinatal LAV/HTLV III infection: attempt at prognostic evaluation.

Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Longitudinal study of 18 children with perinatal LAV/HTLV III infection: attempt at prognostic evaluation.

J Pediatr. 1986 Dec;109(6):965-70. Unique Identifier : AIDSLINE MED/87060359
Blanche S; Le Deist F; Fischer A; Veber F; Debre M; Chamaret S; Montagnier L; Griscelli C

Abstract: We performed a longitudinal study (mean follow-up 19.5 months, range 3 to 42 months) in 18 consecutive children with clinical symptoms of LAV/HTLV III infection. Twelve patients were born to mothers infected with LAV/HTLV III, and six were infected by blood products administered during the first weeks of life. Immunologic studies included lymphocyte markers, in vitro responses to mitogens and antigens with corresponding skin tests, and antibody response with isoagglutinins, post-vaccination antibodies, and Candida. A serologic profile of antibody to GP110, P18, and P25 LAV/HTLV III antigens by radioimmunoprecipitation assay was also performed. The antigen-induced proliferative responses were normal in 10 patients who had a stable course, but were profoundly impaired in eight others who died or had poor condition with opportunistic infections. These in vitro measurements were well correlated with antigen skin tests. An abnormal antibody response to antigens, a low level of isoagglutinins, and a peculiar profile of LAV/HTLV III antibodies were also frequently observed in these eight patients. These measurements appear to be of prognostic value because they were noticed soon after onset of clinical symptoms.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/*IMMUNOLOGY/ MORTALITY/TRANSMISSION Antibodies, Viral/ANALYSIS Antibody Formation Child, Preschool Failure to Thrive/ETIOLOGY Human Immunity, Cellular Infant Longitudinal Studies Lymphocyte Transformation Opportunistic Infections/ETIOLOGY Prognosis Vaccination JOURNAL ARTICLE

870330
M8730238

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .